Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

CELLINK announces third year extension of collaboration with a global biopharmaceutical company for drug discovery

CELLINK scientists will continue to work side-by-side in AstraZeneca labs, aiming to accelerate discovery of new disease targets and therapeutics. CELLINK, a bioconvergence company focused on the commercialization of innovative technologies for 3D bioprinting and life sciences, announced today that the company has renewed its agreement to collaborate with the global biopharmaceutical company, AstraZeneca, in 2021. Over the previous two years, the teams have examined 3D bioprinting as an automation tool for modeling various diseased and healthy tissues types such as vascularized tumors,

Konecranes closed the syndication of the merger financing arrangement

KONECRANES PLC PRESS RELEASE January 28, 2021 at 09:00 EET Konecranes closed the syndication of the merger financing arrangement Konecranes has closed the syndication regarding an EUR 465 million Term Loan Facility. The Term Loan Facility will be used to support and finance the completion of the merger of Konecranes and Cargotec. The syndication was launched on the 30th November 2020 and the commitments received from the banks in the syndication led to a significant oversubscription. Nordea Bank Abp managed the syndication process as Mandated Lead Arranger, Bookrunner and

Getinge Full Year Report 2020: Intense efforts to support health care and pharmaceutical companies

“We have continued to support health care, and the pharmaceutical companies that are rapidly developing and manufacturing COVID-19 vaccines”, says Mattias Perjos, President & CEO at Getinge. “We also achieved our full-year target of delivering 26,000 advanced ICU ventilators, and the demand for our ECMO therapy products remains high”.During the fourth quarter Getinge also noted a strong order intake in Sterile Transfer linked to COVID-19 vaccine manufacturing, for delivery in 2021. A large part of the business continues to be negatively affected by COVID-19 due to cancelled or postponed

Optomed has established a Scientific Advisory Board

Optomed Plc       Press Release 28 January 2021, at 9.00, Helsinki Optomed has established a Scientific Advisory Board Optomed has established an international scientific advisory board. The board consists of globally recognized and scientifically merited medical doctors specializing in ophthalmology and neuro-ophthalmology, with advanced experience on artificial intelligence applied to detection of ophthalmic conditions. The scientific advisory board consists of the following members: Robert Chang, MD, Associate Professor of Ophthalmology, Stanford University Medical Center,

Invitation: Kemira to publish Financial Statements Bulletin 2020 on February 11, 2021

Kemira Oyj, Press Release, February 11, 2021 at 9.00 am (EET)Invitation: Kemira to publish Financial Statements Bulletin 2020 on February 11, 2021 Kemira Oyj will publish its Financial Statements Bulletin 2020 on Thursday, February 11, 2021 around 8.30 am Finnish time (6.30 am UK time). Webcast for analysts, investors, and media will be held on Thursday, February 11, 2021, starting at 10.30 am (8.30 am UK time). At the webcast, Kemira’s President and CEO Jari Rosendal and CFO Petri Castrén will present the results. The webcast will be held in English and can be followed at www.kemira.

Elypta Granted US Patent for its Liquid Biopsy Method based on Cancer Metabolism

Stockholm, January 27, 2020: The molecular diagnostics firm Elypta announced today that it has been granted a patent by the United States Patent and Trademark Office for its novel liquid biopsy method for cancer diagnostics. The patent (US010895576) concerns a method for screening for renal cell carcinoma, the most common form of kidney cancer, by measuring specific metabolites – glycosaminoglycans (GAGs) – non-invasively, through for example blood or urine samples.Elypta was founded in 2017 following an initial discovery in the Nielsen lab, Chalmers University of Technology in Sweden, that

Grant of Share Options to Incentivise Long-Term Performance

28 January 2021 Independent Oil and Gas plc Grant of Share Options to Incentivise Long-Term Performance   Independent Oil and Gas plc ("IOG" or "the Company"), (AIM: IOG.L), the UK gas company targeting high returns via an infrastructure-led hub strategy, announces that, under its Company Share Option Plan, it has today granted options over, in aggregate, 8,578,907 1p Ordinary Shares in the Company ("Ordinary Shares") to its executive directors, senior management and employees to incentivise long-term performance (the "LTIP Options").   The new LTIP Options, which are set

Notice to Elisa’s Annual General Meeting

ELISA STOCK EXCHANGE RELEASE 28 JANUARY 2021 AT 9:00 AMThe Annual General Meeting of Elisa Corporation (the “Company”) will be held on Thursday, 8 April 2021 at 1:00 pm. The meeting will be held under special arrangements without the presence of shareholders or their proxy representatives at Elisa’s headquarters at Ratavartijankatu 5, Helsinki, Finland. The Board of Directors of the Company has decided on an exceptional meeting procedure based on the temporary legislation approved by the Finnish Parliament on 15 September 2020 (the “Temporary Act”). In order to limit the spread of the

Chumphon - Travel guide for outdoor lovers

Absent from mass tourism and a relatively unknown coastal town, Chumphon is a gateway to Southern Thailand. It offers stunning experiences. Perfect for outdoorsy and off-the beaten path activity seekers.   Most travellers rush through the province to more popular, bursting destinations such as Phuket, Koh Samui, Koh Pha-ngan or Koh Lanta, seeing nothing else. But those who have visited Chumphon would classify it as “Thailand as it was used to be”. Here you can find endless beaches that are almost completely empty, no all inclusive hotels, no jetski, but tranquility that is

Paulig takes part in the development of new bio-based packaging material to replace fossil plastic

Paulig is participating in a research project in which renewable and recyclable material is being developed for the food industry to replace fossil plastic. The project, which has now progressed to the industrial testing phase, is led by VTT Technical Research Centre of Finland, which has developed Thermocell plastic film using cellulose and fatty acids. This development work supports Paulig’s objective of switching to using only recyclable packages that are made from renewable or recycled materials by 2030.   VTT has discovered that cellulose can be used as a bio-based

Advances in cellulose-based food packaging material move to testing phase of industrial production

Press release 28 January, 2021 VTT is testing Thermocell plastic film made of cellulose and fatty acids in the production of food packaging in cooperation with Arla Foods, Paulig, and Wipak.  Thermocell plastic material, which is made from renewable components, is to be used in the same way as fossil-based plastic. Thanks to the development work, many features of the film already meet the requirements of the food industry, and cooperation has advanced to the testing of industrial production.Renewable origin and recyclability of packaging materials are of increasing interest to both

Liseberg deploys new data centre solution from Proact for streamlined IT operations and enhanced security

Liseberg has assigned Proact to help modernise its IT infrastructure. Its new data centre solution, designed and delivered by Proact, comprises a hyperconverged system which integrates servers and storage, and a high-performance backup solution which also provides enhanced protection against cyberthreats.Following procurement, the amusement park Liseberg, Sweden’s largest tourist destination, has signed Proact as their partner for a major initiative to update its IT infrastructure. The key objectives for the investment are to simplify operations and administration of the data centre

Nexam Chemical Holding AB (publ) Year-End Report 1 January – 31 December 2020

Strong finish of 2020 with best quarter so farFourth quarter at a glance Significant events: · Continued profitable growth, +46% compared to the corresponding quarter in 2019. · Both Performance Chemical, + 70%, and Performance Masterbatch, + 26%, are growing compared to the corresponding quarter in 2019. · Good order intake during the quarter, indicates a good start to 2021. · New product series launched for the polyester fiber area. · Settlement reached with Uponor Innovation AB regarding patent rights for applications concerning polyethylene pipes applications. The

Wärtsilä's Board of Directors decided on a new share-based incentive scheme

Wärtsilä Corporation Stock Exchange Release 28 January 2021 at 9.00 a.m. (EET)Wärtsilä's Board of Directors decided on a new share-based incentive scheme The Board of Directors of Wärtsilä Corporation has decided on the establishment of a new share-based long-term incentive scheme for the company’s management and selected key employees. The incentive scheme comprises a Performance Share Plan (“PSP”). The objectives of the share-based long-term incentive scheme are to align the interests of Wärtsilä’s management and key employees with those of the company’s shareholders and, thus, to

Lagercrantz Interim Report 2020/21 Q3

Third quarter (1 October – 31 December 2020) · Net revenue totalled MSEK 1,078 (1,099). · Operating profit (EBITA) increased by 8 percent to MSEK 168 (156), equivalent to an operating margin of 15.6 percent (14.2). · Profit after financial items increased by 8 percent to MSEK 139 (129). · Profit after taxes increased by 6 percent to MSEK 111 (105) and earnings per share (after dilution and carried out split) amounted to SEK 0.54 (0.52). · Cash flow from operating activities increased to MSEK 226 (178). · Return on equity for the latest 12-month period amounted to 22

Cloetta AB interim report Q4: October – December 2020

Taking actions to mitigate the impact of COVID-19 as the previous sales recovery transitioned into a new slowdown during the quarter.·Net sales for the quarter decreased by 14.9 per cent to SEK 1,466m (1,722), including a negative effect of 2.6 per cent due to exchange rate fluctuations. · Sales of branded packaged products decreased organically by –3.6 per cent during the quarter, comprised of –1.4 per cent for October, –3.4 per cent for November, and –6.8 per cent for December. · Sales of pick & mix declined organically by –35.9 per cent during the quarter, comprised of –38.5

SAS and Apollo extend partnership in record contract

SAS and Apollo are expanding their partnership regarding charter flights in a contract which covers three summer and three winter seasons through to 2024, with an option for an extension of a further two years to 2026. The partnership with Apollo represents SAS’ largest contract with a charter operator and is worth around SEK 3.4 billion over the first three years.The contract means SAS remains the main partner for Apollo’s charter flights from Scandinavia for the duration of the contract. SAS will fly Apollo customers to and from 24 locations across Sweden, Denmark and Norway to 51

Orexo Q4 2020, incl. Full Year Report

ZUBSOLV® stable and strong EBIT, despite challenging market due to Covid-19  Q4 2020 highlights · Total net revenues of SEK 159.2 m (238.1 last year, 196.2 m excl. Abstral® EU and US) · Net earnings of SEK -49.6 m (38.9) · EBITDA of SEK 1.0 m (85.8) · US Pharma segment (ZUBSOLV® US) net revenues of SEK 143.1 m (190.5), EBIT of SEK 94.4 m (95.5) · Cash flow from operating activities of SEK -11.2 m (60.2), cash balance of SEK 505.3 m (816.8) · Secured a preferred position for ZUBSOLV® as the only branded product on national commercial and Medicare Part D formularies

SRV Group Plc: Proposals of the Shareholders’ Nomination Board to the Annual General Meeting 2021

SRV GROUP PLC     STOCK EXCHANGE RELEASE     28 JANUARY 2021      09:00 EET SRV Group Plc: Proposals of the Shareholders’ Nomination Board to the Annual General Meeting 2021 SRV Group Plc’s Annual General Meeting 2020 established a Shareholders’ Nomination Board to prepare annually proposals concerning the composition and remuneration of the Board of Directors. SRV Group Plc’s Shareholders’ Nomination Board proposes to the Annual General Meeting of SRV Group Plc that five members will be elected to the Board of Directors. Shareholders’ Nomination Board proposes that present

Statement by the Board of Directors of Recipharm regarding the public offer from Roar BidCo

The Board of Directors unanimously recommends the shareholders and holders of convertible bonds to accept the offer from Roar BidCo. This statement is made by the board of directors of Recipharm AB (publ) (“Recipharm”) pursuant to Rule II.19 of the Nasdaq Stockholm Takeover Rules (the ”Takeover Rules”). The Offer On 14 December 2020, EQT IX, through Roar BidCo AB (the “Offeror”), announced a public offer of SEK 220 per share to the shareholders of Recipharm after having submitted an indicative offer to the board of SEK 196 per share at an initial stage. Today, 28 January 2021, the

Roar BidCo AB announces an increased recommended offer to the shareholders and Holders of Convertible Bonds in Recipharm AB (publ) that cannot be increased

The increased consideration amounts to SEK 232 per share and SEK 1,504,295 per Convertible Bond. On 14 December 2020, EQT IX[1 ]("EQT IX"), through Roar BidCo AB[2][ ]("Roar BidCo"), announced a public offer to the shareholders and holders of the Senior Unsecured Convertible Bonds (the "Convertible Bonds") ("Holders of Convertible Bonds") in Recipharm AB (publ) ("Recipharm" or the "Company") to tender all their shares[3] and Convertible Bonds to Roar BidCo for SEK 220 in cash per share and SEK 1,427,010 in cash per SEK 1,000,000 in aggregate principal amount of Convertible Bonds (the "

Recipharm AB publishes report for the fourth quarter and full year 2020

October – December 2020 · Net sales amounted to SEK 2,812 million (1,981), an increase of 42% · EBITA increased by 65% and amounted to SEK 378 million (230) corresponding to an EBITA margin of 13.5% (11.6) · Operating profit (EBIT) amounted to SEK 339 million (117) and was affected by non-recurring items of SEK +54 million (-52) · Profit after tax amounted to SEK 223 million (90) corresponding to a net margin of 7.9% (4.5) · Earnings per share amounted to SEK 2.20 (1.32) before dilution and SEK 2.19 (1.32) after dilution. Core EPS amounted to SEK 1.40 (2.55) · Leverage

BioInvent Phase I/IIa data suggest BI-1206 restores activity of rituximab in relapsed non-Hodgkin’s lymphoma patients

· Responses in 6 out of 9 patients evaluated provide exciting evidence that BI-1206 has the potential to restore activity of rituximab in non-Hodgkin’s lymphoma patients who have relapsed after treatment with rituximab · Long-lasting complete responses observed in two patients beyond 12 months · Key opinion leader (KOL) call to discuss results today, January 28, at 5.30 p.m. CET (11:30 a.m. ET)   Lund, Sweden – January 28, 2021 – BioInvent International AB (“BioInvent”) (OMXS: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-

There are no items matching the current filter
There are no more items matching the current filter
Back to top